[Pathogenetic mechanisms of traumatic brain disease and main lines of their treatment].
To assess efficacy and tolerability of axamon (ipidacrine) in the complex therapy of patients with cranial-brain injuries, 40 patients have been studied. Patients of the main group (20 persons) received, along with traditional therapy, axamon in dose 0,02 g 3 times daily during 2 months and patients of the control group (20 persons) received only traditional therapy. Clinical examination and assessment with NIS, Autonomic Symptoms Questionnaire, Hamilton anxiety scale, electrophysiological study (magnetic diagnostics, electroneuromyography with investigation of somatosensory evoked potentials, brain CT (MRI) have been conducted at the beginning of treatment and 1 and 2 months after. Axamon demonstrated the highest efficacy (p<0.05) in stopping anxiety symptoms in patients of the main group in the 1st month of treatment. After 2 months, a significant improvement of patient's state in the main group assessed by NIS and Hamilton anxiety scale (p<0.05) was found. Data of electrophysiological and neuroimaging study revealed significant positive changes reflected in the normalization of intracerebral conductance and resolution of structural changes of brain substances in the injury. Side-effects of the drug were brief and did not lead to stopping treatment.
Zhivolupov
S A
SA
Samartsev
I N
IN
Kolomentsev
S V
SV
D000368:Aged; D000634:Aminoquinolines / Q000627:therapeutic use*; D001007:Anxiety / Q000209:etiology / Q000517:prevention & control; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006259:Craniocerebral Trauma / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography; D004576:Electromyography; D005073:Evoked Potentials, Somatosensory; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D011795:Surveys and Questionnaires; D014057:Tomography, X-Ray Computed; D015599:Trauma Severity Indices; D016896:Treatment Outcome
D000634:Aminoquinolines; D002800:Cholinesterase Inhibitors; C049860:amiridine